LONA
LeonaBio, Inc.Healthcare · $14M market cap
Verdict
We can't put a fair value on LONA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow LONA
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 26, 2026: no open-market purchases and 3 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Questions about LONA
Are insiders buying LONA?
Since Oct 26, 2026: no open-market purchases and 3 other filings (stock awards, tax withholding and similar).
How can I check LONA's value myself?
Use the free Sticker Price calculator, already filled with LONA's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About LeonaBio, Inc.
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 26, 2026. How the Payback Price works